Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 5 uppsatser.

Tez (Tıpta Uzmanlık) - Süleyman Demirel Üniversitesi, Tıp Fakültesi, Beyin Cerrahi Anabilim Dalı, 2007. / Bibliyografya var.

Thesis (M.Sc.), Memorial University of Newfoundland, Faculty of Medicine,1999. / Typescript. Bibliography: leaves 100-118.

Introduction: Canadian First Nations experience a significantly higher rate of Mycobacterium tuberculosis (MTB) infection than non-Indigenous Canadians. Th17 cells are a subset of CD4+ T cells that are distinguished by their production of Interleukin-17A (IL-17A), an important cytokine for defense against mycobacteria. IL-17 is a primary contributor to the formation and stabilization of the lung granuloma, a biological containment vessel to protect the host from tuberculosis (TB). Past research with First Nations people has identified single nucleotide polymorphisms (SNPs) in the Th1 and Th2 immune pathways may affect their disease risk. However, SNPs in key Th17 related genes and the P2RX7 gene have not been explored in First Nations despite their important role against infectious diseases. Hypothesis: This research hypothesizes that distinct First Nations groups (Dene, Cree and Saulteaux) will have a different frequencies of SNPs in the key Th17 immunity related genes (IL-17A, IL-17AR, IL-23R, and IFN-γR) and the P2RX7 gene, as compared to a non-Indigenous Canadian group. Methods: SNP profiles (IL-17A rs2275913, IL-17RA rs4819554, IL-23R rs10889677, IFN-γR rs2234711 and P2RX7 rs3751143) were identified through literature research and the NCBI database was used for identifying gene motifs, primer locations and Restriction Enzyme cut sites. Polymerase Chain Reaction and Restriction Fragment Length Polymorphism analysis was performed on and visualized on agarose gel to determine specific allele frequencies. Four different Manitoba First Nations communities; the Northern Dene (Dene 1 N=69. Dene 2 N=52), Central Cree (N=46), and Southern Saulteaux (N=56), participated in this research and their SNP profiles were compared to a non-Indigenous Canadian cohort (N=99). Results: Allele frequencies for IL-17A were statistically different for every First Nation community when compared to the non-Indigenous cohort (Dene 1 p=0.0043, Dene 2 p=0.0000, Cree p=0.0001, Saulteaux p=0.0000). Allele frequencies for IL-17RA were statistically different for every First Nation community except Saulteaux when compared to the non-Indigenous cohort (Dene 1 p=0.0000, Dene 2 p=0.0028, Cree p=0.0000). Allele frequencies for IL-23R were statistically different for Dene 1 and Saulteaux community when compared to the non-Indigenous cohort (Dene 1 p=0.0002, Saulteaux p=0.0000). Allele frequencies for IFN-R were statistically different for Cree community when compared to the non-Indigenous cohort (Cree p=0.0026). Allele frequencies for P2RX7 were statistically different for both Dene communities when compared to the non-Indigenous cohort (Dene 1 p=0.0000, Dene 2 p=0.0000). Conclusions: An effective Th17 response is required to bring Th1 cells to infected tissues and to balance inflammatory responses. Functional SNPs may compromise an appropriate immune response and contribute to disease. This study demonstrate that the non-Indigenous population maintained a significantly different genetic profile when compared to the First Nations populations. / October 2016

To date, the cellular mechanisms involved in the progression of diseases characterized by chronic inflammation, such as rheumatoid arthritis (RA), remain largely unknown. However, cell-to-cell contact interactions between CD4+ helper T (Th) cells and monocytes have been implicated in the induction and maintenance of pro-inflammatory cytokine synthesis that is characteristic to the pathogenesis of RA. One such cytokine produced during monocyte-Th cell contact is interleukin (IL)-1 β, a mediator directly involved in the characteristic tissue destruction that occurs in the synovia of individuals with RA. Previous studies in our laboratories have shown that ligation of CD40 on monocytes with CD40 ligand (CD40L) present on activated Th cells induces monocyte IL-1β synthesis and rescues monocytes from apoptosis. These findings suggest a role for CD40 signaling of monocyte activation in the exacerbation and maintenance of chronic inflammatory responses. This dissertation represents efforts to elucidate components of the CD40 signaling pathway critical to monocyte activation and how CD40-mediated signaling events are modulated by the anti-inflammatory cytokines IL-4 and IL-10. Using either monocytes isolated from human peripheral blood or a monocytic cell line (THP-1), cellular kinases and transcription factors activated upon CD40 ligation were examined by western blot analyses and electrophoretic mobility shift assays (EMSA), respectively. CD40-dependent interleukin-1β synthesis in monocytes was abrogated by inhibitors of protein tyrosine kinase (PTK) activity but not by inhibitors of protein kinase C (PKC). The extracellular signal-regulated kinases 1 and 2 (Erk1/Erk2) mitogen-activated protein kinases (MAPK's) were specifically activated upon CD40 ligation, and specific inhibition of Erk1/Erk2 activation diminished IL-10 production in a dose-dependent manner. Both IL-4 and IL-10 reduced Erk1/Erk2 activation and synergized in this effect. Finally, STAT3, a member of the family of transcription factors involved in cytokine signaling, was highly phosphorylated in monocytes treated with IL-10 or with IL-10 and IL-4 in combination but not with IL-4 alone. Together these results suggest that in monocytes (1) CD40-mediated IL-1β synthesis and NF-κB activation require PTK activity, (2) CD40-mediated IL-1β production is critically dependent upon Erk1/Erk2 activity, (3) both IL-4 and IL-10 target the Erk1/Erk2 signaling cascade in the downregulation of IL-1β synthesis, (4) IL-4 and IL-10 have divergent effects on the CD40 signaling pathway in that these cytokines are synergistic with respect to their ability to inhibit CD40-mediated Erk1/Erk2 activation and IL-1β synthesis, and differ in their ability to block CD40-mediated rescue from apoptosis, and (5) STAT3 activation may be directly involved in the downregulatory effects of IL-10 on CD40 signaling. (Abstract shortened by UMI.)

Interleukin-10 ist ein Paradebeispiel eines immunhemmenden Zytokins. Es konnte nachgewiesen werden, dass eine Reihe von Tumoren Interleukin-10 produziert, um einer Antitumor-Immunantwort zu entgehen. Viele Studien haben sich mit dem Einfluss von Interleukin-10 auf die antigenpräsentierenden Fähigkeiten der Dendritischen Zellen beschäftigt. Es gibt eindeutige Hinweise, dass der Effekt von tumorproduziertem Interleukin-10 nicht nur in einer hemmenden Wirkung auf die Ausreifung Dendritischer Zellen besteht, sondern dass Interleukin-10 zu einer Reduktion der Anzahl an Dendritischen Zellen führen kann. Ziel dieser Arbeit ist es daher, den Mechanismus für eine solche depletierende Wirkung auf die Dendritischen Zellen zu analysieren. Hierzu wurden die Effekte von Interleukin-10 auf die frühe Differenzierung von Dendritischen Zellen aus Monozyten untersucht. Die Zugabe von Interleukin-10 zu einem Differenzierungscocktail aus Interleukin-4 und Granulozyten/Makrophagen-Kolonie-stimulierendem-Faktor führt zu einer nachhaltigen Hemmung des Differenzierungsprozesses von Monozyten zu Dendritischen Zellen. Bereits 48h nach Beginn der Zellkultur konnte mit Hilfe von cDNA-Microarray-Analysen gezeigt werden, dass Interleukin-10 nicht nur einen Differenzierungs-hemmenden Effekt ausübt, sondern auch die Entstehung aberranter Zellphänotypen bewirkt. In weiteren Experimenten konnte gezeigt werden, dass die Effekte des Interleukin-10 in der frühen Differenzierungsphase weitgehend irreversibel sind. Zusammenfassend können die Ergebnisse zur Erklärung beitragen, wie es bei Patienten mit Tumoren unter dem Einfluss von Interleukin-10 zu einer Reduktion der absoluten Zahl Dendritischer Zellen kommen kann.

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.

Les allergies aux produits chimiques et aux médicaments constituent un problème majeur de santé publique. L’objectif de ce travail est de mieux comprendre l’interaction entre les cellules dendritiques (DC) et les lymphocytes T (LT) dans les allergies induites par les haptènes métalliques (nickel et cobalt) et les médicaments [benzylpénicilline (BP)]. En présence des signaux de danger, les DC acquièrent un phénotype dit « mature » et présentent l’antigène apprêté aux LT spécifiques de cet antigène. Les LT représentent les cellules effectrices responsables d’une manière directe ou non des symptômes observés lors des réactions allergiques. Dans un premier temps, nous montrons que le nickel est capable d’induire un ratio d’interleukines (IL) IL-23/IL-12p70 élevé dans les DC favorisant ainsi la polarisation Th17 qui est détectée chez la majorité des patients allergiques au nickel. Nous montrons aussi pour la première fois une production de l’IL-27 par les DC activées par le nickel. Nous avons ensuite montré l’implication du TLR4 et de la voie Jak-STAT dans la régulation des cytokines membres de la famille de l’IL-12. L’activation de la voie Jak-STAT est nécessaire pour la réponse Th1 en favorisant la production de l’IL-12p70 et en inhibant la production de l’IL-23 par les DC activées par du nickel. Par ailleurs, nous avons identifié et, pour la première fois, une activation du facteur de transcription NFIL-3, au sein des DC, par le nickel et le cobalt voire d’une manière plus intense avec ce dernier. D’autre part, nous avons mis en évidence l’existence d’un répertoire de LT naïfs CD4+ et CD8+, provenant de la population générale, spécifiques du nickel. L’activation de ces LT requiert les molécules du complexe majeur d’histocompatibilité (CMH) et ils présentent un faible taux de réactivité croisée avec le cobalt. Simultanément, nous avons mis en évidence la possibilité de détecter des LT naïfs CD8+ spécifiques de la BP. L’activation de ces LT dépend des molécules du CMH de classe I et du protéasome. D’une manière générale, notre travail contribue à une meilleure compréhension des mécanismes des réactions allergiques d’une part, en montrant la fine régulation des cytokines membres de la famille de l’IL-12 dans les DC et d’autre part en élucidant les mécanismes de l’immunisation contre les molécules allergisantes. / Drug and chemical allergy is a major public health concern. The aim of this work is to understand the interaction between dendritic cells (DCs) and T-lymphocytes (LT) in allergic manifestations induced by metallic haptens (nickel and cobalt) and benzylpenicillin (BP). DCs capture the antigen, start maturation, migrate to the regional lymph node and activate hapten-specific T-cells. The latter will represent the effector cells responsible directly or not for the symptoms observed during allergic reactions. We showed that nickel induced a high ratio of interleukin (IL) IL-23 compared to IL-12p70 in DCs leading to Th17 polarization as seen in allergic patients. We also showed for the first time the production of IL-27 by nickel-activated DCs. Moreover, we showed the involvement of TLR4 and Jak-STAT pathways in IL-12 cytokine family regulation. The activation of the Jak-STAT pathway seems to maintain the IL-23/IL-12p70 balance by limiting IL-23 production and promoting Th1 polarization. Furthermore, we identified for the first time the activation of NFIL-3 in DC by nickel and cobalt, more intensely with the latter. In addition, nickel-recognizing CD4+ and CD8+ naïve T-cells repertoire was identified from the general population. These positive T-cells were shown to recognize nickel in the context of major histocompatibility complex (MHC) molecules. We also showed that a low frequency of nickel-recognizing CD4+ naïve T-cells cross-reacted with cobalt. Simultaneously, we showed the possibility of detecting a naïve CD8+ T-cells repertoire for BP. The activation of these specific T-cells requires MHC class I molecule and proteasome. In resume, our work contributes to a better understanding of allergic reactions, on one hand, by studying the fine regulation of the IL-12 cytokines family in DCs and on the other hand, by clarifying the mechanisms of immunization against drugs and chemicals.

Master of Science / Department of Anatomy and Physiology / Lei Wang / Jishu Shi / Transforming growth factor beta (TGF-β) and interleukin-1β (IL-1β) are both up-regulated in high grade gliomas and their elevated activities have been associated with prognosis in glioma patients. It is known that TGF-β is involved in proliferation and maintenance of glioma stem cells. In this study, I evaluated whether IL-1β also plays an important role in glioma stem cell development. Glioma stem cells are usually identified by using a sphere assay where glioma stem cells proliferate as neurospheres in serum free medium (SFM) in the presence of two growth factors: EGF and bFGF. However, LN229, a human glioblastoma cell line does not form neurospheres in SFM, suggesting that LN229 cells contain very few stem cells. I found that combination of IL-1β and TGF-β, but not IL-1β or TGF-β alone induced LN229 cells to grow as neurospheres in SFM. Furthermore, quantitative RT-PCR analyses show that the expression of stem cell markers (Nestin, Bmi1, Notch2, and LIF), cytokines (IL-1β, IL-6 and IL-8) and invasive genes (SIP1, β-integrin and N-Cadherin) are significantly enhanced in IL-1β /TGF-β induced spheres compared to the control. Using an invasion assay, drug resistance test, and colony assay, I found that LN229 sphere cells induced by IL-1β and TGF-β are more invasive, have increased drug resistant ability, and are more oncogenic in comparison to the control. Together, these results suggest that IL-1β cooperates with TGF-β to induce glioma stem-like cell phenotype.

No description available.